News
Featured
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed that of all previous years. The WGND is tracking 19 drug candidates that have initiated or completed a Phase 1 clinical trial for use in treating Tuberculosis. Most have been or are currently being evaluated in a Phase 2 clinical trial and one has made it to Phase 3. These 19 do...
News
18 Mar 2010
World Health Organization 18 MARCH 2010 | GENEVA | WASHINGTON DC — In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says. For example, 28...
17 Mar 2010
Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and...
15 Mar 2010
Zebrafish as TB animal model When studying an infection it’s important to have access to a model for examining the progression of disease. In tuberculosis research, such model systems range from mice to guinea pigs to primates, with many species in between. Lalita Ramakrishnan has spent much of her...
10 Mar 2010
Dr. Barbara Laughon Dr. Barbara Laughon works in the Office of the Director, Division of Microbiology and Infectious Diseases at the National Institute of Allergy & Infectious Diseases (NIH/NIAID) . She is also a Core Group member of the Working Group on New TB Drugs and is the Candidates...
9 Mar 2010
From the TB Alert press release: New TB Campaign is Offering Free TB Awareness Resources www.thetruthabouttb.org African HIV Policy Network (AHPN) , together with TB Alert , the UK’s national tuberculosis charity, is encouraging black African organisations to get involved in World TB Day, and is...
8 Mar 2010
autophagy by any other name... The WGND blog is in the R&D vanguard! Recently, Nick Be wrote a post highlighting the activation of the cellular ‘self-eating’ mechanism known as autophagy in the elimination of TB from an infected individual. On March 5, 2010, Cell published a paper by Kumar and...
4 Mar 2010
Prof. Hans Rosling Compared to the widespread news coverage during the swine flu outbreak, TB receives little coverage, especially when you calculate the ratio of news hits to mortality. During a 13 day period in April and May of 2009, the WHO confirmed 31 deaths from swine flu. In that same period...
3 Mar 2010
Detailed view of the ligand-binding site of EthR co-crystallized with BDM31381 (EthRInhibitor) Developing new TB drugs is inhibited by so many factors – namely: The flow through the TB drug pipeline is slow at best. Despite decades of hard work, we still use the demanding regimen developed 50 years...
1 Mar 2010
source: http://www.glsynthesis.com/drug-discovery.html Drug discovery teams around the world have been actively selecting targets that are likely to be important in killing dormant or very slowly replicating tuberculosis in an effort to shorten the time to cure; for drug sensitive TB, six to nine...
1 Mar 2010
This week we highlight two recent papers in TB R&D – TB and HIV treatment and PA-824. Tuberculosis is the leading cause of the death in HIV positive individuals in the developing world. Major challenges exist in treating both diseases simultaneously as drug-drug interactions are common between...
28 Feb 2010
Norma Muñoz Former MDR-TB Patient This video appeared on the Washington Post’s website . Patients who develop multi-drug resistant tuberculosis face an arduous course of medical treatment. What’s worse, many say, is being ostracized by friends and neighbors who fear the dreaded disease.
24 Feb 2010
Aren't These Lives Worth Saving, Too? This is a guest blog jointly submitted by Jerald C. Sadoff, MD, the President & Chief Executive Officer of the Aeras Global TB Vaccine Foundation and Mel Spigelman, MD, the President & Chief Executive Officer of the Global Alliance for TB Drug...
24 Feb 2010
Dr. Jacques Grosset Dr. Jacques Grosset’s biography is excerpted from his staff page on the Johns Hopkins Medicine website . Since the beginning of my professional life I have been involved in research to improve the control of tuberculosis, mainly by improving treatment of tuberculosis and...
22 Feb 2010
A few recent reports track the progress being made by the Stop TB Partnership and TB research funding trends from 2005-2008. As global TB efforts increase in the areas of research, drug, vaccine and diagnostics development, greater emphasis has been placed upon funding. Particularly in light of the...
18 Feb 2010
This interview originally appeared on Planeta Salud’s website . Pere Joan Cardona For 15 years, Dr. Cardona has focused his studies on infection with Mycobacterium tuberculosis (Mtb) has developed a hypothesis and dynamics of tuberculosis infection, which could explain why the Koch bacillus...
